---
title: "The Nasdaq Biotechnology Index once fell more than 3.1%, as the research results for lung disease drugs were unsatisfactory, Regeneron Pharma dropped over 16%, and European stocks Sanofi also fell more than 7% at one point"
description: "The Nasdaq Biotechnology Index once fell over 3.1%, currently narrowing to 2.38%. Regeneron Pharma dropped over 16%, and Sanofi once fell over 7%. The clinical trial results of the lung disease drug I"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/242615398.md"
published_at: "2025-05-30T14:33:00.000Z"
---

# The Nasdaq Biotechnology Index once fell more than 3.1%, as the research results for lung disease drugs were unsatisfactory, Regeneron Pharma dropped over 16%, and European stocks Sanofi also fell more than 7% at one point

> The Nasdaq Biotechnology Index once fell over 3.1%, currently narrowing to 2.38%. Regeneron Pharma dropped over 16%, and Sanofi once fell over 7%. The clinical trial results of the lung disease drug Itepekimab disclosed by the two companies were disappointing, with some studies not meeting primary endpoints, and they are in discussions with regulatory authorities regarding follow-up matters

The Nasdaq Biotechnology Index once fell over 3.14%, with the decline currently narrowing to 2.38%.

Component stock Summit Therapeutics Plc. is currently down 25.09%, Regeneron Pharma is down 16.49%, and Vir Biotech is down 6.07%, ranking third from the bottom.

On May 30th, ahead of European stock trading, data disclosed by Sanofi and Regeneron Pharma showed mixed results for the clinical trial of the drug Itepekimab, used for treating lung diseases—while achieving the primary endpoint in one Phase III study, it failed to achieve the primary endpoint in another study. The two companies are analyzing the data and will discuss it with (various) regulatory agencies.

Sanofi's stock price in Paris gapped down, with the decline once expanding to 7.11%, making it the worst performer among the "Eleven Warriors" in European stocks

### Related Stocks

- [REGN.US - Regeneron Pharma](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Zydus Lifesciences 推出生物仿制药 Aflibercept 2 毫克 Anyra | Zydus Lifesciences Ltd：推出生物类似药 Aflibercept 2 mg，并与再生元制药和拜耳签署协议 | [Link](https://longbridge.com/en/news/276299857.md) |
| 再生元制药｜10-K：2025 财年营收 143 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/274827698.md) |
| 拜切公司｜10-K：2025 财年营收 10.37 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276487321.md) |
| 拜切公司｜8-K：2025 财年 Q4 营收 2.64 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276442357.md) |
| NOW 公司｜8-K：2025 财年营收 28.2 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276438920.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.